Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / Lars Lannfelt / BioArctic

Lars Lannfelt & BioArctic

2 shared events · Importance 3 · Last updated May 28, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (2)
30
Business
Eisai Projects Leqembi Revenue Growth
Lars Lannfelt: Professor Lars Lannfelt's discovery of the Arctic mutation in Alzheimer's disease formed the basis for the development of Lecanemab by BioArctic.
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
0
Regulatory
Leqembi Iqlik PDUFA Date Extended
May 08, 2026 · 14 articles
NEWSDESK
Explore this relationship live

Track how Lars Lannfelt and BioArctic interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.